Johnson & Johnson invests in TECLens refractive technology startup
Click Here to Manage Email Alerts
Key takeaways:
- TECLens is developing a non-incisional refractive correction procedure that incorporates corneal cross-linking.
- Presbyopia is indicated for the first refractive correction clinical studies of the treatment.
Johnson & Johnson Innovation closed a transaction of Series A funding as the co-lead investor in TECLens, an early-stage startup focusing on a non-incisional procedure for refractive correction.
TECLens aims to develop a noninvasive treatment to reshape the cornea without laser ablation by utilizing quantitative corneal cross-linking technology and the company’s CXLens device, according to information on Johnson & Johnson’s website.
“J&J is excited to invest in this early ophthalmic innovation which complements our existing expertise in contact lens and refractive and cataract surgical solutions, including presbyopia correction,” Peter Menziuso, company group chairman of Johnson & Johnson Vision, told Healio. “The treatment modality of TECLens’ innovation has the potential to significantly improve access to care for some of the world’s most complex vision correction needs like presbyopia, progressive keratoconus, low myopia, hyperopia and astigmatism.”
The “repeatable and titratable” office-based treatment could be an alternative solution to traditional refractive surgeries, particularly for patients who are not good candidates for other refractive solutions. It is designed to deliver a computationally optimized UV light pattern directly to the eye from a fiber optic-connected scleral contact lens and a dose of riboflavin.
The treatment will also utilize ultrasound to monitor the correction effect in real time to further increase the precision of the outcome.
TECLens is planning the first refractive correction clinical studies of the treatment, with presbyopia as the initial indication.
“We will continue to track progress with TECLens to support their clinical development milestones for this innovative refractive technology,” Menziuso said.
Collapse
Read more about
Click Here to Manage Email Alerts